^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CYTO NK-102

    i
    Other names: CYTO NK-102, CYTO-102, COH06
    Associations

    News

    Trials
    Company:
    City of Hope, CytoImmune
    Drug class:
    NK cell stimulant
    Related drugs:
    Associations

    News

    Trials
    11ms
    Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors (clinicaltrials.gov)
    P1, N=21, Recruiting, City of Hope Medical Center | Trial completion date: Jan 2025 --> Sep 2025 | Trial primary completion date: Jan 2025 --> Sep 2025
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • cyclophosphamide • fludarabine IV • CYTO NK-102